Vantictumab (Anti-FZD)
Product Specifications
CAS Number
1345009-45-1
Synonyms
OMP-18R5
Target
Wnt/beta-catenin
Applications
Cytoskeletal Signaling
Additionnal Information
Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC401073-500 1x 500 µL
HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740158-500 1x 500 µL
Cytokeratin 17 (E3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740485-100 1x 100 µL
ODC-1 (Ornithine Decarboxylase-1) (ODC1/485), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042083-500 1x 500 µL
CD86 (Dendritic Cells Maturation Marker) (rC86/1146), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040689-500 1x 500 µL
Cytokeratin 8 (K8.8), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details